Nadja Kopp

发表

Therapeutics , Targets , and Chemical Biology BCL 2 Suppresses PARP 1 Function and Nonapoptotic Cell Death

A. Letai, G. Shapiro, M. Davids, 2012 .

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Eric Vangrevelinghe, Andrew L. Kung, James E. Bradner, 2011, The Journal of experimental medicine.

Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance

B. Ebert, G. Adelmant, J. Marto, 2014, Nature Medicine.

Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia

G. Abel, R. Erlich, A. Lane, 2013, Leukemia.

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Robert Kridel, Donna Neuberg, Alessandro Pastore, 2015, The Lancet. Oncology.

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.

Christopher J. Ott, T. Bowman, J. Bradner, 2012, Blood.

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

A. Letai, S. Sallan, M. Harris, 2015, Cancer cell.

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

N. Harris, S. Pileri, J. Teruya-Feldstein, 2012, Blood.

Identification of a synthetic peptide inducing cross-reactive antibodies binding to Rhipicephalus (Boophilus) decoloratus, Rhipicephalus (Boophilus) microplus, Hyalomma anatolicum anatolicum and Rhipicephalus appendiculatus BM86 homologues.

M. Amacker, C. Nitsch, C. Daubenberger, 2009, Vaccine.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

BCL2 suppresses PARP1 function and nonapoptotic cell death.

A. Letai, G. Shapiro, M. Davids, 2012, Cancer research.

Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones

R. Greil, H. Hackl, D. Weinstock, 2016, Oncotarget.

lymphoma A targeted mutational landscape of angioimmunoblastic T-cell

N. Harris, S. Pileri, J. Teruya-Feldstein, 2014 .

Next-Generation cDNA Screening for Oncogene and Resistance Phenotypes

T. Sullivan, A. Lane, S. Rodig, 2012, PloS one.

Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.

A. Pandey, Jun Zhong, Min-Sik Kim, 2012, Blood.

Genetic resistance to JAK 2 enzymatic inhibitors is overcome by HSP 90 inhibition

D. Erdmann, M. McKeown, J. Bradner, 2012 .

Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities.

D. Neuberg, G. Pinkus, D. Milner, 2016, Blood advances.

Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.

D. Neuberg, J. Kutok, T. Sullivan, 2012, Cancer discovery.

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.

S. Rodig, A. Christodoulou, A. Christie, 2016, Blood.

Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance

F. Jardin, N. Harris, D. Neuberg, 2013 .

Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma

R. Greil, H. Hackl, D. Weinstock, 2014 .

Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance

B. Ebert, G. Adelmant, J. Marto, 2014, Nature Medicine.

GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition

G. Adelmant, J. Marto, Kutlu G. Elpek, 2014 .